Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma
Status:
Not yet recruiting
Trial end date:
2027-08-02
Target enrollment:
Participant gender:
Summary
This feasibility study will assess the clinical potential of a new imaging approach to detect
viable high grade glioma (HGG) in pediatric and adult patients after standard of care
radiation therapy (RT) with or without concurrent temozolomide (TMZ). Study participants will
undergo simultaneous positron emission tomography/magnetic resonance imaging (PET/MRI) with
O-([2-[F-18]fluoroethyl)-L-tyrosine (FET, amino acid transport) and
1H-1-(3-[F-18]fluoro-2-hydroxypropyl)-2-nitroimidazole (FMISO, hypoxia) at the time of
standard of care imaging after completion of RT. The presence of viable tumor at this time
point will be assessed on a per patient basis. Study participants will be followed clinically
and with standard of care (SOC) imaging for up to 2 years after completion of PET/MRI to
determine the nature of lesions seen on investigational imaging and to obtain patient outcome
data. The imaging data will also be used to develop a semi-automated workflow suitable for
implementation in clinical trials and standard of care PET/MRI studies.